Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is a… Read more
Ascendis Pharma AS (ASND) - Net Assets
Latest net assets as of December 2025: $-162.75 Million USD
Based on the latest financial reports, Ascendis Pharma AS (ASND) has net assets worth $-162.75 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.30 Billion) and total liabilities ($1.46 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-162.75 Million |
| % of Total Assets | -12.5% |
| Annual Growth Rate | N/A |
| 5-Year Change | -118.42% |
| 10-Year Change | -192.15% |
| Growth Volatility | 231.46 |
Ascendis Pharma AS - Net Assets Trend (2011–2025)
This chart illustrates how Ascendis Pharma AS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ascendis Pharma AS (2011–2025)
The table below shows the annual net assets of Ascendis Pharma AS from 2011 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-162.75 Million | -53.97% |
| 2024-12-31 | $-105.71 Million | +27.45% |
| 2023-12-31 | $-145.70 Million | -155.32% |
| 2022-12-31 | $263.35 Million | -70.20% |
| 2021-12-31 | $883.63 Million | +5.36% |
| 2020-12-31 | $838.71 Million | +40.46% |
| 2019-12-31 | $597.11 Million | +113.22% |
| 2018-12-31 | $280.05 Million | +49.59% |
| 2017-12-31 | $187.21 Million | +6.00% |
| 2016-12-31 | $176.61 Million | +46.78% |
| 2015-12-31 | $120.33 Million | +162.67% |
| 2014-12-31 | $45.81 Million | +627.03% |
| 2013-12-31 | $6.30 Million | +304.95% |
| 2012-12-31 | $1.56 Million | +567.81% |
| 2011-12-31 | $233.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ascendis Pharma AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 269604284200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.32 Million | % |
| Other Comprehensive Income | $-1.75 Million | % |
| Other Components | $2.53 Billion | % |
| Total Equity | $-162.75 Million | 100.00% |
Ascendis Pharma AS Competitors by Market Cap
The table below lists competitors of Ascendis Pharma AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TransUnion
NYSE:TRU
|
$13.91 Billion |
|
Api Group Corp
NYSE:APG
|
$13.93 Billion |
|
Omega Healthcare Investors Inc
NYSE:OHI
|
$13.93 Billion |
|
Wal-Mart de México S.A.B. de C.V
MX:WALMEX
|
$13.96 Billion |
|
Carlisle Companies Incorporated
NYSE:CSL
|
$13.88 Billion |
|
NEXT plc
PINK:NXGPF
|
$13.87 Billion |
|
Repsol S.A
OTCQX:REPYF
|
$13.85 Billion |
|
Samsung Life
KO:032830
|
$13.84 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ascendis Pharma AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -105,706,000 to -162,751,650, a change of -57,045,650.
- Net loss of 219,034,140 reduced equity.
- Share repurchases of 16,709,428 reduced equity.
- Other comprehensive income decreased equity by 3,537,251.
- Other factors increased equity by 182,235,169.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-219.03 Million | -134.58% |
| Share Repurchases | $16.71 Million | -10.27% |
| Other Comprehensive Income | $-3.54 Million | -2.17% |
| Other Changes | $182.24 Million | +111.97% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Ascendis Pharma AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.14 | $228.06 | x |
| 2013-12-31 | $0.58 | $228.06 | x |
| 2014-12-31 | $2.70 | $228.06 | x |
| 2015-12-31 | $5.06 | $228.06 | x |
| 2016-12-31 | $6.65 | $228.06 | x |
| 2017-12-31 | $5.57 | $228.06 | x |
| 2018-12-31 | $6.82 | $228.06 | x |
| 2019-12-31 | $12.84 | $228.06 | x |
| 2020-12-31 | $16.57 | $228.06 | x |
| 2021-12-31 | $16.13 | $228.06 | x |
| 2022-12-31 | $4.70 | $228.06 | x |
| 2023-12-31 | $-2.59 | $228.06 | x |
| 2024-12-31 | $-1.83 | $228.06 | x |
| 2025-12-31 | $-2.69 | $228.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ascendis Pharma AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -31.67%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-29.01%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 80.33% | 8.02% | 0.61x | 16.33x | $1.09 Million |
| 2013 | 64.74% | 19.99% | 0.76x | 4.24x | $3.45 Million |
| 2014 | -21.08% | -69.07% | 0.24x | 1.28x | $-14.24 Million |
| 2015 | -27.36% | -405.54% | 0.06x | 1.10x | $-44.95 Million |
| 2016 | -38.79% | -1487.30% | 0.02x | 1.08x | $-86.17 Million |
| 2017 | -66.18% | -8097.84% | 0.01x | 1.13x | $-142.62 Million |
| 2018 | -46.45% | -1229.53% | 0.03x | 1.14x | $-158.10 Million |
| 2019 | -36.51% | -1630.03% | 0.02x | 1.13x | $-277.73 Million |
| 2020 | -49.95% | -6025.53% | 0.01x | 1.17x | $-502.83 Million |
| 2021 | -43.41% | -4931.56% | 0.01x | 1.23x | $-471.94 Million |
| 2022 | -221.45% | -1139.63% | 0.05x | 4.14x | $-609.53 Million |
| 2023 | 0.00% | -180.51% | 0.32x | 0.00x | $-466.88 Million |
| 2024 | 0.00% | -103.97% | 0.31x | 0.00x | $-367.51 Million |
| 2025 | 0.00% | -31.67% | 0.53x | 0.00x | $-202.76 Million |
Industry Comparison
This section compares Ascendis Pharma AS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ascendis Pharma AS (ASND) | $-162.75 Million | 80.33% | N/A | $13.88 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |